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Abstract
Body: INTRODUCTION: Nebulized pentamidine is used in the prevention of
pneumocystis carinii pneumonia in immunosuppressed patients. A specific
nebulizer with characteristics to ensure deep lung deposition is required. It must
include a circuit with expiratory filter preventing the dissemination of droplets
into the environment. The reference nebulizer for pentamidine delivery is the
Respirgard II®. All nebulizers with comparable properties could be used for the
nebulization. AIMS AND OBJECTIVES: The aim of this work was to evaluate
and to compare the inhaled dose between the Respirgard II® and the Isoneb®.
METHODS: The nebulizers were connected to a dual chamber lung model
(5600i Dual Adult Training/Test Lung®,Michigan Instrument Inc.) simulating usual
breathing pattern of an adult patient. A solution of pentamidine (300mg/6mL
sterile water) was nebulized during 20 minutes. We measured in triplicate the
inhaled dose by weighting the filter positioned between the nebulizer and the...
Document type : Communication à un colloque (Conference Paper)
Référence bibliographique
Audag, Nicolas ; Sokal, Etienne ; Smets, Françoise ; Van der Linden, Dimitri ; Stéphenne,
Xavier ; et. al. Comparison of pentamidine inhaled dose with two different nebulizers.ERS
(European Respiratory Society) International Congress 2014 ((Germany) Munich, du 06/09/2014
au 10/09/2014). In: The European Respiratory Journal, Vol. 44, no. Suppl 58, p. P1233 (2014)
 COMPARISON OF INHALED DOSE WITH PENTAMIDINE NEBULIZERS: 
ISONEB® vs. RESPIRGARD II®  
Audag N., Van der linden D., Smets F., Stephenne X., Liistro G., Sokal E., Reychler G. 
Cliniques universitaires Saint-Luc (UCL) - Brussels - Belgium 
Aims 
• Pentamidine in nebulized form is one of the drugs listed in the primary or secondary prevention of 
pneumocystis carinii pneumonia in immunosuppressed patients.  
 
• This nebulization requires a nebulizer with specific characteristics. These features are the presence of a circuit 
with expiratory filter preventing the dissemination of droplets into the environment (pentamidine may be toxic) 
and secondly, to ensure a fine particle size allowing deep lung deposition. 
 
• The reference nebulizer used for pentamidine nebulization is currently the Respirgard II®, a disposable 
pneumatic nebulizer. Several studies remark that all nebulizers with comparable properties could be used for 
the nebulization. 
 
• The aim of our work is to evaluate and compare the results between the reference nebulizer Respirgard II ®, 
and one of these nebulizers available on the market, the Isoneb ®. 
• This in vitro study is the first step in the comparison of the two nebulizers.  
 
• We found no significant difference in the inhaled dose. 
 
• We observed a difference in residual solution but none in calculated lost dose. It could be explained by the drugs concentration in the cuve or by a difference of 
deposition in the device, in the one-way valves and in the filter positioned on the nebulizer expiratory branch. Nevertheless we have no measure to prove it. The 
difference in the internal volume is highly significative, it could explain a different deposition in the device. 
 
• However the effectiveness of pneumocystis carinii pneumonia prophylaxis is based on the inhaled dose and pulmonary deposition. We will have to measure the 
pulmonary deposition in a second study  to compare the relative effectiveness of the two nebulizers.  
Results 
• In this in vitro study, we have tested the inhaled dose 
corresponding to the two nebulizers.                  
•Based on our results, we can conclude that both nebulizer 
have similar properties. 
 
Methods 
• A solution of pentamidine (300mg/6mL sterile water) was nebulized by a Respirgard II® (Vital Signs,             
New Jersey, USA) (RII) or by an Iso-NEB® (Teleflex, Pennsylvania, USA) (Iso). 
 
• Nebulizers (Iso and RII) were connected to a dual chamber lung model (5600i Dual Adult Training/Test Lung®, 
Michigan Instrument Inc., Michigan, USA) simulating usual breathing pattern of an adult. Respiratory frequency 
and tidal volume driving by a ventilator (SERVO-I®, Maquet, Rastatt, Germany) to the lung model were 15 
cycle/min, 500 mL respectively. 
 
• During the nebulization, a filter (filter 1) was interposed between the nebulizer and the lung model.  The filter 
was weighed before the nebulization and after drying for 24 hours at ambient air. The resulting weight is the 
inhaled dose. We expressed the inhaled dose in percentage of the nominal dose. 
 
• The nebulizer cup was weighted before and directly after nebulization. Residual solution was obtained by 
subtracting the weight of the empty nebulizer cup and the weight of the nebulizer cup at the end of the 
nebulization.  
 
• The lost dose (expressed in percentage of the nominal dose) represents the difference between the inhaled 
dose and the nominal dose. 
 
• Nebulization was stopped for each nebulizer after 20 minutes. 
 
• We measured the internal volume of the nebulizers (without cup and filters) after the nebulization. 
 
Discussion Conclusion 
Schematic diagram of experimental devices used in the in vitro study 
  Parameters 
Nebulizer 
p value 
Isoneb® Respirgard II® 
Inhaled dose (% nominal dose) 32.9 ± 10 29.5 ± 3.3 0.611 
Residual solution (g) 0.986 ± 0.089 1.575 ± 0.317 0.036 
Lost dose (% nominal dose) 67.1 ± 10 70.4 ± 3.3 0.611 
Internal volume (cm³) 106.3 ± 0.6 110.3 ± 0.6 0.001 
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